<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00012207</url>
  </required_header>
  <id_info>
    <org_study_id>1503.00</org_study_id>
    <secondary_id>FHCRC-1503.00</secondary_id>
    <secondary_id>NCI-G01-1921</secondary_id>
    <secondary_id>CDR0000068494</secondary_id>
    <nct_id>NCT00012207</nct_id>
  </id_info>
  <brief_title>Biological Therapy After Chemotherapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma</brief_title>
  <official_title>A Phase I Study To Evaluate The Safety Of Cellular Immunotherapy Using Genetically Modified Autologous Cd20-Specific Cd8+ T Cell Clones For Patients With Relapsed Cd20+ Indolent Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Biological therapies use different ways to stimulate the immune system and stop&#xD;
      cancer cells from growing. Drugs used in chemotherapy use different ways to stop cancer cells&#xD;
      from dividing so they stop growing or die. Combining biological therapy with chemotherapy may&#xD;
      kill more cancer cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of biological therapy after chemotherapy in&#xD;
      treating patients who have relapsed or refractory non-Hodgkin's lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the safety and toxicity of cellular immunotherapy with autologous CD8+&#xD;
           cytotoxic T-lymphocyte clones after chemotherapy comprising cyclophosphamide,&#xD;
           vincristine, and prednisone in patients with relapsed or refractory CD20+ indolent&#xD;
           lymphomas or mantle cell lymphoma.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the duration of in vivo persistence of adoptively transferred CD20-specific&#xD;
           CD8+ cytotoxic T-lymphocyte clones in the absence and presence of subcutaneous&#xD;
           interleukin-2 in these patients.&#xD;
&#xD;
        -  Assess the trafficking of CD8+ cytotoxic T-lymphocyte clones to lymph nodes in these&#xD;
           patients treated with this regimen.&#xD;
&#xD;
        -  Determine immune response and tumor response in patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is an open-label, pilot study.&#xD;
&#xD;
        -  Leukapheresis: Patients undergo leukapheresis. Selected CD20-specific CD8+ cells are&#xD;
           cultured to expand the cytotoxic T lymphocytes (CTL), which are then cloned.&#xD;
&#xD;
        -  Chemotherapy:&#xD;
&#xD;
      Patients receive oral cyclophosphamide and oral prednisone on days 1-5 and vincristine IV on&#xD;
      day 1. Courses repeat every 3-4 weeks for a total of 6 courses.&#xD;
&#xD;
        -  Immune cell infusion:&#xD;
&#xD;
      Beginning 4 weeks after the last course of chemotherapy (and lymph nodes ≤ 5 cm diameter or ≤&#xD;
      5,000 circulating CD20+ lymphocytes/mm^3), patients receive autologous CD8+ CTL clones IV&#xD;
      over 30 minutes. Courses repeat every 2-5 days for a total of 3 courses in the absence of&#xD;
      disease progression or unacceptable toxicity. The last 6 patients receive interleukin-2&#xD;
      subcutaneously every 12 hours for 14 days, beginning 2 hours after the last infusion of CD8+&#xD;
      CTL clones.&#xD;
&#xD;
      After course 2 or 3 of immune cells, all patients undergo surgical lymph node biopsy to&#xD;
      determine if immune cells are moving to the lymph nodes.&#xD;
&#xD;
      Patients are followed monthly for 1 year and then annually for 2 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 12 patients will be accrued for this study within 4 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2000</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and toxicity by NCI CTC toxicity scale in patients w/ recurr. or refract. CD20+ follicular lymphoma who are not candidates for high dose chemoradiotx and stem cell transplant during each infusion, weekly for 4 wks and then monthly for a yr</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of in vivo persistence of adoptively transferred CD20-specific CD8+ T cell clones by flow cytometry and quantitative polymerase chain reaction (qPCR) during each infusion, weekly for 4 weeks, and then monthly for a year</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trafficking of CD8+ CD20-specific T cell clones to lymph nodes by Gamma camera imaging during each infusion, weekly for 4 weeks, and then monthly for a year</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of host anti-scFvFc:zeta (and anti-NeoR) immune responses by ELISA and chromium release assays during each infusion, weekly for 4 weeks, and then monthly for a year</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor responses to cyclophosphamide, vincristine, and prednisone (CVP) and to cytotoxic T-lymphocyte (CTL) infusions by Cheson criteria during each infusion, weekly for 4 weeks, and then monthly for a year</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aldesleukin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>therapeutic autologous lymphocytes</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Immunohistopathologically documented relapsed or refractory CD20+ indolent lymphomas&#xD;
             or mantle cell lymphoma&#xD;
&#xD;
               -  Indolent B-cell lymphomas including any of the following subtypes:&#xD;
&#xD;
                    -  Follicular lymphoma (grade I, II, or III)&#xD;
&#xD;
                    -  Small lymphocytic lymphoma or chronic lymphocytic leukemia&#xD;
&#xD;
                    -  Marginal zone lymphoma (splenic, nodal, and extra-nodal)&#xD;
&#xD;
                    -  Lymphoplasmacytoid lymphoma&#xD;
&#xD;
          -  Ineligible for or unwilling to participate in other FHCRC/UWMC protocols&#xD;
&#xD;
          -  Serological evidence of prior exposure to Epstein-Barr virus&#xD;
&#xD;
          -  Must agree to undergo peripheral blood drawing, bone marrow biopsy, lymph node biopsy,&#xD;
             and nuclear medicine imaging&#xD;
&#xD;
          -  Must agree to cytoreductive chemotherapy if necessary to reduce lymph nodes to &lt; 5 cm&#xD;
             in diameter or circulating B lymphocyte counts to &lt; 5,000/mm^3&#xD;
&#xD;
          -  No pulmonary involvement&#xD;
&#xD;
          -  No CNS involvement&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  Any age&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 90 days&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  No active hepatitis B infection&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No HIV positivity&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No history of hypersensitivity reactions to murine proteins&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  At least 4 months since prior rituximab, tositumomab, or ibritumomab&#xD;
&#xD;
          -  No prior allogeneic stem cell transplantation&#xD;
&#xD;
          -  No other concurrent immunotherapy (e.g., interferons, vaccines, or other cellular&#xD;
             products)&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 2 years since prior fludarabine or cladribine&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy and recovered&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  No concurrent systemic corticosteroids except to treat toxicity from chemotherapy or&#xD;
             cellular immunotherapy&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  At least 4 weeks since prior immunosuppressive therapy and recovered&#xD;
&#xD;
          -  No concurrent pentoxifylline&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oliver W. Press, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Fred Hutchinson Cancer Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010-3000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington School of Medicine</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Till BG, Jensen MC, Wang J, Chen EY, Wood BL, Greisman HA, Qian X, James SE, Raubitschek A, Forman SJ, Gopal AK, Pagel JM, Lindgren CG, Greenberg PD, Riddell SR, Press OW. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood. 2008 Sep 15;112(6):2261-71. doi: 10.1182/blood-2007-12-128843. Epub 2008 May 28.</citation>
    <PMID>18509084</PMID>
  </results_reference>
  <verification_date>August 2010</verification_date>
  <study_first_submitted>March 3, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>August 20, 2010</last_update_submitted>
  <last_update_submitted_qc>August 20, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 24, 2010</last_update_posted>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aldesleukin</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

